Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Monday, October 2nd.
A number of other equities research analysts also recently issued reports on MTEM. Stifel Nicolaus reaffirmed a “hold” rating and issued a $0.40 price objective on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. Ladenburg Thalmann Financial Services started coverage on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th.
Shares of Threshold Pharmaceuticals (MTEM) traded down 19.45% during mid-day trading on Monday, reaching $9.11. The company’s stock had a trading volume of 766,727 shares. Threshold Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $11.88. The company has a 50 day moving average of $5.63 and a 200-day moving average of $5.59. The firm’s market capitalization is $244.89 million.
Threshold Pharmaceuticals (NASDAQ:MTEM) last issued its quarterly earnings data on Monday, July 31st. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.77) by $0.99. The firm had revenue of $3.00 million during the quarter. Equities research analysts forecast that Threshold Pharmaceuticals will post ($0.74) EPS for the current year.
Threshold Pharmaceuticals Company Profile
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.